Shamburg News · 8-K filed Nov 16, 2026, 8:30 AM EST
HCW Biologics Reports Third Quarter 2026 Financial Results and Clinical Development Highlights
HCWB · HCW Biologics Inc.
- Earnings
- Financial statements
- Materiality: high
On November 16, 2026, HCW Biologics Inc. reported financial results for the quarter ended September 30, 2026. Third-quarter revenues were $55,463, compared with $15,606 a year earlier, and the net loss was $3,222,829, compared with $4,554,336. The company stated that substantial doubt exists about its ability to continue as a going concern without additional funding.
Source: SEC EDGAR, Form 8-K, Items 2.02, 9.01, accession 0001493152-26-052053.
Written from the filing by Shamburg Markets. Figures are as reported by the company.